Can Faster Aspart Be Used to Optimize Glycemic Control With Insulin Pump Therapy? From Expectations to Lessons Learned After a Year of Use in the United States

Autor:	Grazia Aleppo, Bruce Bode, Anders L. Carlson
Rok vydání:	2022
Předmět:	endocrine system diseases Endocrinology Diabetes and Metabolism Internal Medicine nutritional and metabolic diseases hormones hormone substitutes and hormone antagonists
Zdroj:	Clinical Diabetes. 40:413-424
ISSN:	1945-4953 0891-8929
DOI:	10.2337/cd21-0056
Popis:	Fast-acting insulin aspart (faster aspart) is an ultra-rapid-acting formulation of insulin aspart developed to more closely match the prandial endogenous insulin profile, and its accelerated absorption kinetics are expected to provide clinical benefits for patients using insulin pump therapy. A head-to-head trial versus the original insulin aspart formulation in pump therapy did not demonstrate superiority of faster aspart in terms of A1C reduction, but pump settings were not optimized for the pharmacokinetic/pharmacodynamic profile of faster aspart. Nevertheless, meal test and continuous glucose monitoring data suggest that faster aspart is beneficial for postprandial glucose control, and a case study is presented illustrating excellent results using this insulin in pump therapy. Frequent blood glucose monitoring and appropriate patient education are vital for success.
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1de2bd22c3d0a988618aaa00afb44522 https://doi.org/10.2337/cd21-0056 Zobrazit plný text záznamu